[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Blinatumomab.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Blinatumomab.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Blinatumomab.]
[L04AA27, fingolimod, Blinatumomab may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Blinatumomab.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Blinatumomab.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Blinatumomab.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Blinatumomab.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Blinatumomab.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Blinatumomab.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Blinatumomab.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Blinatumomab.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Blinatumomab.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Ticlopidine is combined with Blinatumomab.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Blinatumomab.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Blinatumomab.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Blinatumomab.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Blinatumomab.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Blinatumomab.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Blinatumomab.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Blinatumomab.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Blinatumomab.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Blinatumomab.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Blinatumomab.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Blinatumomab.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Rivaroxaban is combined with Blinatumomab.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Ticagrelor is combined with Blinatumomab.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Blinatumomab.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Blinatumomab.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Blinatumomab.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Blinatumomab.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Warfarin is combined with Blinatumomab.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Blinatumomab.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Blinatumomab.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blinatumomab.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Blinatumomab.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Blinatumomab.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Blinatumomab.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Blinatumomab.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Blinatumomab.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Blinatumomab.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Blinatumomab.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Blinatumomab.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Blinatumomab.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blinatumomab.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Blinatumomab.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carfilzomib is combined with Blinatumomab.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Bosutinib is combined with Blinatumomab.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Teriflunomide is combined with Blinatumomab.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Blinatumomab.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Blinatumomab.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Blinatumomab.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Blinatumomab.]
[L04AA29, tofacitinib, Blinatumomab may increase the immunosuppressive activities of Tofacitinib.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Ponatinib is combined with Blinatumomab.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Apixaban is combined with Blinatumomab.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Raxibacumab is combined with Blinatumomab.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Blinatumomab.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Blinatumomab.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Blinatumomab.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Benzocaine.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Everolimus is combined with Blinatumomab.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Benzyl alcohol.]
[L03AA14, lipegfilgrastim, Blinatumomab may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ibrutinib.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Apremilast is combined with Blinatumomab.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Blinatumomab.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Blinatumomab.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Blinatumomab.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Blinatumomab.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Vorapaxar is combined with Blinatumomab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Blinatumomab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Blinatumomab.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Blinatumomab.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Peginterferon beta-1a.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Blinatumomab.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Dulaglutide is combined with Blinatumomab.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Blinatumomab.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Blinatumomab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Antilymphocyte immunoglobulin (horse).]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Olaparib.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Nivolumab is combined with Blinatumomab.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Blinatumomab.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Blinatumomab.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Blinatumomab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Panobinostat is combined with Blinatumomab.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Blinatumomab.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Blinatumomab.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Blinatumomab.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Alirocumab.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Evolocumab.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Idarucizumab.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Blinatumomab.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Asfotase alfa.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Blinatumomab.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Daratumumab.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Necitumumab.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Blinatumomab.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tetanus immune globulin, human.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ixekizumab.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Blinatumomab.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Blinatumomab.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Atezolizumab.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Blinatumomab.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Blinatumomab.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Blinatumomab.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Brodalumab.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Avelumab.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Blinatumomab.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Dupilumab.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Blinatumomab.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Blinatumomab.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Blinatumomab.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Durvalumab.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Blinatumomab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Blinatumomab.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Blinatumomab.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Blinatumomab.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Blinatumomab.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Blinatumomab.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Blinatumomab.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Blinatumomab.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Blinatumomab.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Blinatumomab.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Benralizumab.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Emicizumab.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Capsaicin.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Blinatumomab.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Blinatumomab.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Erenumab.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Baricitinib.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Mogamulizumab.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Galcanezumab.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Blinatumomab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Blinatumomab.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Blinatumomab.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Siponimod.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Romosozumab.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Blinatumomab.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Risankizumab.]
[L01FX14, polatuzumab vedotin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Polatuzumab vedotin.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Upadacitinib.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Blinatumomab.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Brolucizumab.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Blinatumomab.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Trastuzumab deruxtecan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Diroximel fumarate.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Blinatumomab.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Eptinezumab.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ozanimod.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Blinatumomab.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Blinatumomab.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Blinatumomab.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Sacituzumab govitecan.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Blinatumomab.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Blinatumomab is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Blinatumomab.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Satralizumab.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Blinatumomab.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Blinatumomab.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Blinatumomab.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Margetuximab.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Voclosporin.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Blinatumomab.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Blinatumomab.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ponesimod.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blinatumomab.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Blinatumomab.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Amivantamab.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Sotrovimab.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Blinatumomab.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Aducanumab.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Anifrolumab.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tisotumab vedotin.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ropeginterferon alfa-2b.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tralokinumab.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Sutimlimab.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Blinatumomab.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Levobupivacaine.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Deucravacitinib.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tremelimumab.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Blinatumomab is combined with Clozapine.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ublituximab.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Blinatumomab.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Blinatumomab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Blinatumomab.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Blinatumomab.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Blinatumomab.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Blinatumomab.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Blinatumomab.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Blinatumomab.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Blinatumomab.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Blinatumomab.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Blinatumomab.]
[S01XA18, cyclosporine, Blinatumomab may increase the immunosuppressive activities of Cyclosporine.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Blinatumomab.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Blinatumomab.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Blinatumomab.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Blinatumomab.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Blinatumomab.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Blinatumomab.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Blinatumomab.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Blinatumomab.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Blinatumomab.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Blinatumomab.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Blinatumomab.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Blinatumomab.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Clopidogrel is combined with Blinatumomab.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Cinchocaine.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Blinatumomab.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Ixabepilone is combined with Blinatumomab.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Blinatumomab.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Difluocortolone.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Blinatumomab.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Blinatumomab.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Blinatumomab.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Pramocaine.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Blinatumomab.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Blinatumomab.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Blinatumomab.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Blinatumomab.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Human Rho(D) immune globulin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Natalizumab.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Blinatumomab.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Blinatumomab.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Blinatumomab.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Blinatumomab.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Blinatumomab.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Blinatumomab.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Blinatumomab.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Blinatumomab.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Blinatumomab.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Blinatumomab.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Human varicella-zoster immune globulin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Blinatumomab.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Blinatumomab.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Blinatumomab.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Blinatumomab.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Blinatumomab.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Blinatumomab.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Blinatumomab.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Blinatumomab.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Blinatumomab.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Blinatumomab.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Blinatumomab.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Fluticasone.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Blinatumomab.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Blinatumomab.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Blinatumomab.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Blinatumomab.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Blinatumomab.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Blinatumomab.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Blinatumomab.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Blinatumomab.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Blinatumomab.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Blinatumomab.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Blinatumomab.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Blinatumomab.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Blinatumomab.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Blinatumomab.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Blinatumomab.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Blinatumomab.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Blinatumomab.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Blinatumomab.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Blinatumomab.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Blinatumomab.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Blinatumomab.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Blinatumomab.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Blinatumomab.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Blinatumomab.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Blinatumomab.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Blinatumomab.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Blinatumomab.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Blinatumomab.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Blinatumomab.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Blinatumomab.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Blinatumomab.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Blinatumomab.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Blinatumomab.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Blinatumomab.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Blinatumomab.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Blinatumomab.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Blinatumomab.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Blinatumomab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Articaine.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Blinatumomab.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Blinatumomab.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Blinatumomab.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Blinatumomab.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Blinatumomab.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Blinatumomab.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Blinatumomab.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Blinatumomab.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Blinatumomab.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Lidocaine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Blinatumomab.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Temsirolimus is combined with Blinatumomab.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Blinatumomab.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Nilotinib is combined with Blinatumomab.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Blinatumomab.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Blinatumomab.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Blinatumomab.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Blinatumomab.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Blinatumomab.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Mepivacaine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Blinatumomab.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Blinatumomab.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Blinatumomab.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Blinatumomab.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Blinatumomab.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Blinatumomab.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Blinatumomab.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Blinatumomab.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Blinatumomab.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Blinatumomab.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Blinatumomab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Pazopanib is combined with Blinatumomab.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Blinatumomab.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Blinatumomab.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Blinatumomab.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Blinatumomab.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Docetaxel is combined with Blinatumomab.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Blinatumomab.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Blinatumomab.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Blinatumomab.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Blinatumomab.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Rilonacept is combined with Blinatumomab.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Blinatumomab.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Blinatumomab.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Blinatumomab.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Blinatumomab.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Blinatumomab.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Blinatumomab.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Blinatumomab.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Blinatumomab.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Blinatumomab.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Edrecolomab.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Blinatumomab.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Blinatumomab.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Blinatumomab.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Blinatumomab.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Blinatumomab.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Blinatumomab.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Blinatumomab.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Blinatumomab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Blinatumomab.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Blinatumomab.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Blinatumomab.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Blinatumomab.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Blinatumomab.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Blinatumomab.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Blinatumomab.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Blinatumomab.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Blinatumomab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Blinatumomab.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Blinatumomab.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Blinatumomab.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Blinatumomab.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Hydrocortisone butyrate.]
